Founded in 1999, we are an international biotech company committed to improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, we have formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. Our Key Accomplishments Each of our achievements stands as evidence of our unyielding determination, including: - Multiple approved antibody medicines powered by our innovation - Many proprietary investigational therapies in various stages of development- Inventors of four proprietary technologies - Solid financial base - Building and expanding our capabilities with more than 2,000 employees across our four international locations We are united by our core values:- A passion for innovation - Determination - Integrity - Working as one team and respecting each other When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotech company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinary™ experience. Locations: We are headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. For more information, please visit Genmab.com and follow us on LinkedIn and X.